Hana Barosova

Hana Barosova

Auto-generated profile, based on publicly available information

Hana Barosova

Adolphe Merkle Institute, University of Fribourg, Chemin des Verdiers 4, 1700 Fribourg, Switzerland

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 March 2020 in ACS Nano
Verified
Journal Article
Open access
HBHana Barosova
Hana Barosova
AMAnna G. Maione
Anna G. Maione
DSDedy Septiadi
Dedy Septiadi
MSMonita Sharma
Monita Sharma
LHLaetitia Haeni
Laetitia Haeni
BRBarbara Rothen-Rutishauser
Barbara Rothen-Rutishauser
Expansion in production and commercial use of nanomaterials increases the potential human exposure during the lifecycle of these materials (production, use, and disposal). Inhalation is a primary route of exposure to nanomaterials, therefore it is critical to assess their potential respiratory hazard. Herein, we developed a three dimensional alveolar model (EpiAlveolarTM) consisting of human primary alveolar epithelial cells, fibroblasts, and endothelial cells, with or without macrophages for predicting long-term responses to aerosols. Following thorough characterization of the model, (pro-)inflammatory and (pro-)fibrotic responses based on the adverse outcome pathway concept for lung fibrosis were assessed upon repeated sub-chronic exposures (up to 21 days) to two types of multi-walled carbon nanotubes (MWCNTs), and silica quartz particles. We simulate occupational exposure doses for the MWCNTs (1 – 30 μg/cm2) using an air-liquid interface exposure device (VITROCELL® Cloud) with repeated exposures over 3 weeks. Specific key events leading to the lung fibrosis, such as barrier integrity, release of (pro-)inflammatory, and (pro-)fibrotic markers show the responsiveness of the model. Nanocyl induced, in general, a less pronounced reaction than Mitsui-7, and the cultures with human monocyte-derived macrophages (MDMs) showed the (pro-)inflammatory response at later time-points than without MDMs. In conclusion, we present a robust alveolar model to predict inflammatory and fibrotic responses upon exposure to MWCNTs.

23 February 2020 in Expert Opinion on Drug Delivery
Verified
Journal Article
Closed access
SEStephan Ehrmann
Stephan Ehrmann
OSOtmar Schmid
Otmar Schmid
CDChantal Darquenne
Chantal Darquenne
BRBarbara Rothen-Rutishauser
Barbara Rothen-Rutishauser
JSJosue Sznitman
Josue Sznitman
NHNathalie Heuzé-Vourc'h
Nathalie Heuzé-Vourc'h
Introduction: Pulmonary drug delivery is a complex field of research combining physics which drive aerosol transport and deposition and biology which underpins efficacy and toxicity of inhaled drugs. A myriad of preclinical methods, ranging from in-silico to in-vitro, ex-vivo and in-vivo, can be implemented. Areas covered: The present review covers in-silico mathematical and computational fluid dynamics modelization of aerosol deposition, cascade impactor technology to estimated drug delivery and deposition, advanced in-vitro cell culture methods and associated aerosol exposure, lung-on-chip technology, ex-vivo modeling, in-vivo inhaled drug delivery, lung imaging and longitudinal pharmacokinetic analysis. Expert opinion: No single pre-clinical model can be advocated; all methods are fundamentally complementary and should be implemented based on benefits and drawbacks to answer specific scientific questions. The overall best scientific strategy depends, among others, on the product under investigations, inhalation device design, disease of interest, clinical patient population, previous knowledge. Pre-clinical testing is not to be separated from clinical evaluation, as small proof-of-concept clinical studies or conversely large scale clinical big data may inform pre-clinical testing. The extend of expertise required for such translational research is unlikely to be found in one single laboratory calling for the setup of multinational large-scale research consortiums.

Verified
Journal Article
Open access
PDF file
HBHana Barosova
Hana Barosova
BKBedia Begum Karakocak
Bedia Begum Karakocak
DSDedy Septiadi
Dedy Septiadi
Alke FinkAlke Fink
Alke Fink
VSVicki Stone
Vicki Stone
BRBarbara Rothen-Rutishauser
Barbara Rothen-Rutishauser
In vitro three-dimensional (3D) lung cell models have been thoroughly investigated in recent years and provide a reliable tool to assess the hazard associated with nanomaterials (NMs) released into the air. In this study, a 3D lung co-culture model was optimized to assess the hazard potential of multiwalled carbon nanotubes (MWCNTs), which is known to provoke inflammation and fibrosis, critical adverse outcomes linked to acute and prolonged NM exposure. The lung co-cultures were exposed to MWCNTs at the air-liquid interface (ALI) using the VITROCELL® Cloud system while considering realistic occupational exposure doses. The co-culture model was composed of three human cell lines: alveolar epithelial cells (A549), fibroblasts (MRC-5), and macrophages (differentiated THP-1). The model was exposed to two types of MWCNTs (Mitsui-7 and Nanocyl) at different concentrations (2–10 μg/cm2) to assess the proinflammatory as well as the profibrotic responses after acute (24 h, one exposure) and prolonged (96 h, repeated exposures) exposure cycles. The results showed that acute or prolonged exposure to different concentrations of the tested MWCNTs did not induce cytotoxicity or apparent profibrotic response; however, suggested the onset of proinflammatory response.

10 May 2018 in Archives of Toxicology
Verified
Journal Article
Open access
PDF file
HBHana Barosova
Hana Barosova
SCSavvina Chortarea
Savvina Chortarea
PPPavlína Peikertová
Pavlína Peikertová
Martin J D CliftMartin J D Clift
Martin J D Clift
Alke FinkAlke Fink
Alke Fink
BRBarbara Rothen-Rutishauser
Barbara Rothen-Rutishauser
Wear particles from automotive friction brake pads of various sizes, morphology, and chemical composition are significant contributors towards particulate matter. Knowledge concerning the potential adverse effects following inhalation exposure to brake wear debris is limited. Our aim was, therefore, to generate brake wear particles released from commercial low-metallic and non-asbestos organic automotive brake pads used in mid-size passenger cars by a full-scale brake dynamometer with an environmental chamber simulating urban driving and to deduce their potential hazard in vitro. The collected fractions were analysed using scanning electron microscopy via energy-dispersive X-ray spectroscopy (SEM–EDS) and Raman microspectroscopy. The biological impact of the samples was investigated using a human 3D multicellular model consisting of human epithelial cells (A549) and human primary immune cells (macrophages and dendritic cells) mimicking the human epithelial tissue barrier. The viability, morphology, oxidative stress, and (pro-)inflammatory response of the cells were assessed following 24 h exposure to ~ 12, ~ 24, and ~ 48 µg/cm2 of non-airborne samples and to ~ 3.7 µg/cm2 of different brake wear size fractions (2–4, 1–2, and 0.25–1 µm) applying a pseudo-air–liquid interface approach. Brake wear debris with low-metallic formula does not induce any adverse biological effects to the in vitro lung multicellular model. Brake wear particles from non-asbestos organic formulated pads, however, induced increased (pro-)inflammatory mediator release from the same in vitro system. The latter finding can be attributed to the different particle compositions, specifically the presence of anatase.

21 August 2020 in Frontiers in Bioengineering and Biotechnology
Verified
Journal Article
Open access
PDF file
BDBarbara Drasler
Barbara Drasler
BKBedia Begum Karakocak
Bedia Begum Karakocak
ETEsma Bahar Tankus
Esma Bahar Tankus
HBHana Barosova
Hana Barosova
JAJun Abe
Jun Abe
BRBarbara Rothen-Rutishauser
Barbara Rothen-Rutishauser
A large number of prevalent lung diseases is associated with tissue inflammation. Clinically, corticosteroid therapies are applied systemically or via inhalation for the treatment of lung inflammation, and a number of novel therapies are being developed that require preclinical testing. In alveoli, macrophages and dendritic cells play a key role in initiating and diminishing pro-inflammatory reactions and, in particular, macrophage plasticity (M1 and M2 phenotypes shifts) has been reported to play a significant role in these reactions. Thus far, no studies with in vitro lung epithelial models have tested the comparison between systemic and direct pulmonary drug delivery. Therefore, the aim of this study was to develop an inflamed human alveolar epithelium model and to test the resolution of LPS-induced inflammation in vitro with a corticosteroid, methylprednisolone (MP). A specific focus of the study was the macrophage phenotype shifts in response to these stimuli. First, human monocyte-derived macrophages were examined for phenotype shifts upon exposure to lipopolysaccharide (LPS), followed by treatment with MP. A multicellular human alveolar model, composed of macrophages, dendritic cells, and epithelial cells, was then employed for the development of inflamed models. The models were used to test the anti-inflammatory potency of MP by monitoring the secretion of pro-inflammatory mediators (interleukin [IL]-8, tumor necrosis factor-α [TNF-α], and IL-1β) through four different approaches, mimicking clinical scenarios of inflammation and treatment. In macrophage monocultures, LPS stimulation shifted the phenotype towards M1, as demonstrated by increased release of IL-8 and TNF-α and altered expression of phenotype-associated surface markers (CD86, CD206). MP treatment of inflamed macrophages reversed the phenotype towards M2. In multicellular models, increased pro-inflammatory reactions after LPS exposure were observed, as demonstrated by protein secretion and gene expression measurements. In all scenarios, among the tested mediators the most pronounced anti-inflammatory effect of MP was observed for IL-8. Our findings demonstrate that our inflamed multicellular human lung model is a promising tool for the evaluation of anti-inflammatory potency of drug candidates in vitro. With the presented setup, our model allows a meaningful comparison of the systemic vs. inhalation administration routes for the evaluation of the efficacy of a drug in vitro.

22 August 2017 in Journal of Nanobiotechnology
Verified
Journal Article
Open access
PDF file
JBJean-Pierre Brog
Jean-Pierre Brog
ACAurélien Crochet
Aurélien Crochet
JSJoël Seydoux
Joël Seydoux
Martin J D CliftMartin J D Clift
Martin J D Clift
BBBenoît Baichette
Benoît Baichette
Katharina FrommKatharina Fromm
Katharina Fromm
LiCoO2 is one of the most used cathode materials in Li-ion batteries. Its conventional synthesis requires high temperature (>800 °C) and long heating time (>24 h) to obtain the micronscale rhombohedral layered high-temperature phase of LiCoO2 (HT-LCO). Nanoscale HT-LCO is of interest to improve the battery performance as the lithium (Li+) ion pathway is expected to be shorter in nanoparticles as compared to micron sized ones. Since batteries typically get recycled, the exposure to nanoparticles during this process needs to be evaluated. Several new single source precursors containing lithium (Li+) and cobalt (Co2+) ions, based on alkoxides and aryloxides have been structurally characterized and were thermally transformed into nanoscale HT-LCO at 450 °C within few hours. The size of the nanoparticles depends on the precursor, determining the electrochemical performance. The Li-ion diffusion coefficients of our LiCoO2 nanoparticles improved at least by a factor of 10 compared to commercial one, while showing good reversibility upon charging and discharging. The hazard of occupational exposure to nanoparticles during battery recycling was investigated with an in vitro multicellular lung model. Our heterobimetallic single source precursors allow to dramatically reduce the production temperature and time for HT-LCO. The obtained nanoparticles of LiCoO2 have faster kinetics for Li+ insertion/extraction compared to microparticles. Overall, nano-sized LiCoO2 particles indicate a lower cytotoxic and (pro-)inflammogenic potential in vitro compared to their micron-sized counterparts. However, nanoparticles aggregate in air and behave partially like microparticles.